



KNOWLEDGE SHARING AND CAPACITY BUILDING

- Compatibility/in-use stability studies are **critical to ensure consistent quality** upon preparation and administration.
- Multi-specific therapeutics **require risk-based, end-to-end control strategies**.
- **Further discussion and understanding between industry and regulatory agencies** would be beneficial to align on expectations for label claims, testing requirements, and potential impacts to patient dosing.
- The results of the IQ survey showed a **surprising variety of strategies applied across companies**.

CMC NORTH AMERICA 2026 BY THE NUMBERS



Total Attendees

972




First-Time Attendees

408



Companies Represented

111



Regulators Participated

17



Countries Collaborated

22

Austria | Brazil | Belgium | Canada | Chile | China | Denmark | France | Germany | India | Ireland | Italy | Japan | Netherlands | Puerto Rico | Singapore | South Africa | Sweden | Switzerland | Turkey | United Kingdom | United States

CASSS RESOURCES

Looking for more past meeting content?

Speaker slides, roundtable notes, and video presentations can be accessed through **Papers and Presentations** and **CASSS On Demand** on our website. www.casss.org

